NCT02997358View on ClinicalTrials.gov

Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma

PHASE3CompletedINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

January 18, 2017

Primary Completion Date

July 28, 2021

Study Completion Date

July 28, 2021

Conditions

Uterine or Soft Tissue Leiomyosarcoma

Interventions

DRUG

Doxorubicin

75 mg/m² Day 1 of each 3-weeks cycle

DRUG

Trabectedin

150 μg/m²/day s.c From day 3 to day 9

Trial Locations (1)

94805

Gustave Roussy, Villejuif

All Listed Sponsors

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT02997358 - Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma | Biotech Hunter | Biotech Hunter